(King of Prussia, PA; June 19, 2012) –Theorem Clinical Research, a full-service contract research organization (CRO) providing core clinical research and development services, has launched its new look and tagline, “Think Theorem.”
“The revamped look was designed to further enhance and better incorporate our vision and mission all while highlighting our services,” stated Theorem Clinical Research Chief Executive Officer John Potthoff. “We believe this will effectively communicate the benefits we provide and position us as the partner of choice for the medical therapeutic development industry.”
Theorem Clinical Research specializes in simplifying complex clinical trials and provides expertise in biopharmaceutical development, medical device and diagnostics development, clinical analytics and support in all risk classifications and approval pathways. The company concentrates on complex global Phase I-IV clinical trials with therapeutic expertise in first-in-human, feasibility and combination clinical trials and pivotal and post-surveillance studies along with all classes of external, implantable and active-implantable products.
In addition, Theorem Clinical Research offers unmatched access to Asia because of its experience in conducting one of China’s largest outcome trials. The company has access to investigator sites in more than 30 countries within the Americas, Europe, Middle East and Asia–Pacific.
The new look will be on display June 24-28 in booth #3144 at the Drug Information Association (DIA) 48th Annual Meeting in Philadelphia.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.